Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Page 1
Radiological and long-term clinical response to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease.
Aalbers BL, Mohamed Hoesein FAA, Hofland RW, Bronsveld I, Kruijswijk MA, Schotman S, Slingerland CW, Panhuis H, van der Ent CK, Heijerman HGM. Aalbers BL, et al. Among authors: heijerman hgm. Pediatr Pulmonol. 2023 Aug;58(8):2317-2322. doi: 10.1002/ppul.26486. Epub 2023 May 24. Pediatr Pulmonol. 2023. PMID: 37222401 Clinical Trial.
The effect of azithromycin on sputum inflammatory markers in bronchiectasis.
Terpstra LC, Altenburg J, Doodeman HJ, Piñeros YSS, Lutter R, Heijerman HGM, Boersma WG. Terpstra LC, et al. Among authors: heijerman hgm. BMC Pulm Med. 2023 Apr 29;23(1):151. doi: 10.1186/s12890-023-02444-1. BMC Pulm Med. 2023. PMID: 37118704 Free PMC article.
BACKGROUND: Long term macrolide treatment has been found beneficial in bronchiectasis (BE) -pathogical bronchial dilatation- possibly due to a combined anti-bacterial and immunomodulatory effect. ...
BACKGROUND: Long term macrolide treatment has been found beneficial in bronchiectasis (BE) -pathogical bronchial dilatation- possibly …
The BATTLE study: Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis. Study protocol of a double blind, randomized, placebo-controlled trial: study protocol.
Terpstra LC, Altenburg J, Bronsveld I, Doodeman HJ, Rozemeijer W, Heijerman HGM, Boersma WG. Terpstra LC, et al. Among authors: heijerman hgm. Contemp Clin Trials Commun. 2022 Dec 6;30:101045. doi: 10.1016/j.conctc.2022.101045. eCollection 2022 Dec. Contemp Clin Trials Commun. 2022. PMID: 36531900 Free PMC article.
BACKGROUND: Patients with bronchiectasis typically suffer from chronic symptoms such as a productive cough with or without exacerbations leading to hospitalization, causing reduced quality of life (QoL) and mortality. Long-term inhaled antibiotics to treat chronic bronchia …
BACKGROUND: Patients with bronchiectasis typically suffer from chronic symptoms such as a productive cough with or without exacerbations lea …
Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis.
Terpstra LC, Altenburg J, Bronsveld I, de Kruif MD, Berk Y, Snijders D, Rozemeijer W, Heijerman HGM, Boersma WG. Terpstra LC, et al. Among authors: heijerman hgm. Respir Res. 2022 Dec 3;23(1):330. doi: 10.1186/s12931-022-02243-y. Respir Res. 2022. PMID: 36463180 Free PMC article.
BACKGROUND: Use of long-term tobramycin inhalation solution (TIS) has been shown beneficial in cystic fibrosis (CF) and earlier findings also suggest a benefit in non-CF bronchiectasis. ...No differences were found for the other secondary outcomes. CONCLUSION: Long-term …
BACKGROUND: Use of long-term tobramycin inhalation solution (TIS) has been shown beneficial in cystic fibrosis (CF) and earlier findi …
The effect of maintenance azithromycin on radiological features in patients with bronchiectasis - Analysis from the BAT randomized controlled trial.
Terpstra LC, Altenburg J, Mohamed Hoesein FA, Bronsveld I, Go S, van Rijn PAC, De Jong PA, Heijerman HGM, Boersma WG. Terpstra LC, et al. Among authors: heijerman hgm. Respir Med. 2022 Feb;192:106718. doi: 10.1016/j.rmed.2021.106718. Epub 2021 Dec 28. Respir Med. 2022. PMID: 34974413 Free article. Clinical Trial.
This study was undertaken to prospectively evaluate the effect of long-term azithromycin (AZM) on radiological features in patients with bronchiectasis. ...Especially the consolidation (Bhalla) and parenchymal changes (Brody) sub scores significantly improved (both p=0.030 …
This study was undertaken to prospectively evaluate the effect of long-term azithromycin (AZM) on radiological features in patients w …
Breast development in a 7 year old girl with CF treated with ivacaftor: An indication for personalized dosing?
Jeyaratnam J, van der Meer R, Berkers G, Heijerman HG, Beekman JM, van der Ent CK. Jeyaratnam J, et al. Among authors: heijerman hg. J Cyst Fibros. 2021 Sep;20(5):e63-e66. doi: 10.1016/j.jcf.2021.06.001. Epub 2021 Jun 24. J Cyst Fibros. 2021. PMID: 34175243 Free article.
Substantial progress has been made in the treatment of Cystic fibrosis due to introduction of CFTR modulators. However, little is known about the long term side effects of treatment with these drugs. We here present a 7 year old girl with CF who presented with breast devel …
Substantial progress has been made in the treatment of Cystic fibrosis due to introduction of CFTR modulators. However, little is known abou …
Forskolin-induced swelling of intestinal organoids correlates with disease severity in adults with cystic fibrosis and homozygous F508del mutations.
de Winter-de Groot KM, Berkers G, Marck-van der Wilt REP, van der Meer R, Vonk A, Dekkers JF, Geerdink M, Michel S, Kruisselbrink E, Vries R, Clevers H, Vleggaar FP, Elias SG, Heijerman HGM, van der Ent CK, Beekman JM. de Winter-de Groot KM, et al. Among authors: heijerman hgm. J Cyst Fibros. 2020 Jul;19(4):614-619. doi: 10.1016/j.jcf.2019.10.022. Epub 2019 Nov 15. J Cyst Fibros. 2020. PMID: 31735562 Free article.
These findings suggest that differences at low CFTR residual function may contribute to clinical heterogeneity in F508del homozygous patients and small changes in CFTR residual function might impact long-term disease expression....
These findings suggest that differences at low CFTR residual function may contribute to clinical heterogeneity in F508del homozygous patient …
Pharmacokinetics and safety of tobramycin nebulization with the I-neb and PARI-LC Plus in children with cystic fibrosis: A randomized, crossover study.
van Velzen AJ, Uges JWF, Heijerman HGM, Arets BGM, Nuijsink M, van der Wiel-Kooij EC, van Maarseveen EM, van Zanten GA, Pullens B, Touw DJ, Janssens HM. van Velzen AJ, et al. Among authors: heijerman hgm. Br J Clin Pharmacol. 2019 Sep;85(9):1984-1993. doi: 10.1111/bcp.13988. Epub 2019 Jul 10. Br J Clin Pharmacol. 2019. PMID: 31112621 Free PMC article. Clinical Trial.
CONCLUSIONS: Nebulization of 75 mg TIS with the I-neb in children with cystic fibrosis resulted in comparable systemic exposure to 300 mg TIS with the PARI-LC Plus and was well tolerated and preferred over the PARI-LC Plus. Long-term safety of TIS nebulization should be mo …
CONCLUSIONS: Nebulization of 75 mg TIS with the I-neb in children with cystic fibrosis resulted in comparable systemic exposure to 300 mg TI …
Long-term effects of birth order and age at diagnosis in cystic fibrosis: a sibling cohort study.
Slieker MG, van den Berg JM, Kouwenberg J, van Berkhout FT, Heijerman HG, van der Ent CK. Slieker MG, et al. Among authors: heijerman hg. Pediatr Pulmonol. 2010 Jun;45(6):601-7. doi: 10.1002/ppul.21227. Pediatr Pulmonol. 2010. PMID: 20503286 Free article.
Younger sibs are mostly earlier diagnosed with CF than their older sibs, but might be at risk for an earlier colonization with Pseudomonas aeruginosa (PA) than their older counterparts due to cross-infection within families. AIMS: To analyze the effects of birth order and …
Younger sibs are mostly earlier diagnosed with CF than their older sibs, but might be at risk for an earlier colonization with Pseudomonas a …
Dry powder inhalation versus wet nebulisation delivery of antibiotics in cystic fibrosis patients.
Westerman EM, Heijerman HG, Frijlink HW. Westerman EM, et al. Among authors: heijerman hg. Expert Opin Drug Deliv. 2007 Mar;4(2):91-4. doi: 10.1517/17425247.4.2.91. Expert Opin Drug Deliv. 2007. PMID: 17335406
Adaptive aerosol delivery devices are promising, but do not have a distinct position as yet because of the lack of long-term data. The position of dry powder inhalation of antibiotics in cystic fibrosis treatment is still confined to pilot studies. ...
Adaptive aerosol delivery devices are promising, but do not have a distinct position as yet because of the lack of long-term data. Th …
15 results